Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA (2020 - 2025)

iSpecimen has reported EBITDA over the past 6 years, most recently at -$5.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 17.29% year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$10.5 million, up 16.09%, while the annual FY2025 figure was -$10.5 million, 16.09% up from the prior year.
  • EBITDA for Q4 2025 was -$5.0 million at iSpecimen, down from -$2.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$942644.0 in Q1 2021 and troughed at -$6.0 million in Q4 2024.
  • A 5-year average of -$2.5 million and a median of -$2.3 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 401.15% in 2021 and later skyrocketed 50.35% in 2025.
  • Year by year, EBITDA stood at -$2.0 million in 2021, then fell by 7.35% to -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then tumbled by 110.62% to -$6.0 million in 2024, then increased by 17.29% to -$5.0 million in 2025.
  • Business Quant data shows EBITDA for ISPC at -$5.0 million in Q4 2025, -$2.8 million in Q3 2025, and -$1.0 million in Q2 2025.